LN-145

Phase 2Cell therapy

IIovance Biotherapeutics, Inc.

LN-145 is one of 125 biologic programs targeting Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

124

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Cervical CarcinomaActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Metastatic Non Small Cell Lung CancerRecruiting

Squamous Cell CarcinomaActive, not recruiting

Lung CancerPhase 2

Active, not recruiting

Cervical CarcinomaPhase 2

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Metastatic Non Small Cell Lung CancerPhase 2

Recruiting

Squamous Cell CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

LN-145

IIovance Biotherapeutics, Inc.

Phase 2

1 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

PORTRAZZA

Eli Lilly

Preclinical

8 4

Lenvima

Eisai

Preclinical

6 5

Imjudo

AstraZeneca

Preclinical

5 6

Vizimpro

Pfizer

Preclinical

4 7

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 8

Remeron

OOrganon and Co

Preclinical

1 9

PD-1 Inhibitor

Johnson & Johnson

Preclinical

2 10

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 2Recruiting

Squamous Cell Carcinoma

NCT07288073

Q3 2029

Phase 2Recruiting

Tumor Infiltrating Lymphocytes

NCT03645928

Q4 2031

Phase 2Recruiting

Metastatic Non Small Cell Lung Cancer

NCT04614103

Clinical

Trials by Indication[1]

Squamous Cell Carcinoma2 trials

Study of LN-145/LN-145-S1 Autologous Tumor Infiltrating Lymphocytes in the Treatment of Squamous Cell Carcinoma of the Head & Neck

Completed·IIovance Biotherapeutics, Inc.·Phase 2·NCT03083873·64 enrolled

TIL Therapy in cSCC and MCC

Recruiting·—·Phase 2·NCT07288073·14 enrolled

Tumor Infiltrating Lymphocytes1 trial

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Recruiting·IIovance Biotherapeutics, Inc.·Phase 2·NCT03645928·245 enrolled

Cervical Carcinoma1 trial

Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma

Terminated·IIovance Biotherapeutics, Inc.·Phase 2·NCT03108495·210 enrolled

Non-Small Cell Lung Cancer1 trial

Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer

Withdrawn·IIovance Biotherapeutics, Inc.·Phase 2·NCT03419559

Metastatic Non Small Cell Lung Cancer1 trial

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer

Recruiting·IIovance Biotherapeutics, Inc.·Phase 2·NCT04614103·170 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for LN-145. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LN-145 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LN-145. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Iovance Biotherapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 2[1]
Company: IIovance Biotherapeutics, Inc.

LN-145

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Q3 2029

Q4 2031

Trials by Indication[1]

Squamous Cell Carcinoma2 trials

Tumor Infiltrating Lymphocytes1 trial

Cervical Carcinoma1 trial

Non-Small Cell Lung Cancer1 trial

Metastatic Non Small Cell Lung Cancer1 trial

References

Drug Info

Quick Facts

Related News